Roos van Westrhenen

Has grant

Visiting Senior Vice Lecturer

King’s College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Roos van Westrhenen is a Visiting Senior Vice Lecturer at King's College London, UK. Her research focuses on pharmacogenetics in psychiatry, trauma-focused psychotherapy, and gene-drug interactions. Recent publications include insights into the implementation of pharmacogenetics and its clinical implications, as well as guidelines established by the Dutch Pharmacogenetics Working Group.

Recent Grants

Grant: Close

A New Intervention for implementation of pharmacogenetics in psychiatry

Open Date: 2021-03-01

Close Date: 2026-01-01

Articles (21)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (8)

Mattia Meattini

University of Brescia

ITALY

View details

Magnus Ingelman-Sundberg

Karolinska Institutet

SWEDEN

View details

Raj Jagesar

University of Groningen

NETHERLANDS

View details

Emma de Brabander

University of Maastricht

NETHERLANDS

View details

Per Hoffmann

University of Basel

SWITZERLAND

View details

Martien Kas

Professor of Behavioural Neuroscience

Rijksuniversiteit Groningen

NETHERLANDS

View details

Bea Campforts

University of Maastricht

NETHERLANDS

View details

Jesse Swen

Full professor of clinical pharmacy, in particular translational pharmacogenetics

Leiden University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Roos van Westrhenen

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (21)

PSY-PGx

Telomere length and mitochondrial DNA copy number in association with trauma-focused psychotherapy efficacy

Meta-analyses of pharmacogenetics-guided antidepressant treatment: Reply to milosavljevic

Rare variants and clozapine: Reply

Clinical effects of CYP2D6 phenoconversion in patients with psychosis

A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs

Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between <i>CYP2D6</i>, <i>CYP3A4</i> and <i>CYP1A2</i> and antipsychotics

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between <i>UGT1A1</i> and irinotecan (Nov, 10.1038/s41431-022-01243-2, 2022)

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between <i>UGT1A1</i> and irinotecan

PSY-PGX - A NEW INTERVENTION FOR IMPLEMENTATION OF PHARMACOGENETICS IN PSYCHIATRY: PROGRESS AND CHALLENGES

Pharmacogenomics and the Management of Mood Disorders-A Review

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank

Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review.

Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review

The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.

Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?

Collaborators (8)

Mattia Meattini

Magnus Ingelman-Sundberg

Raj Jagesar

Emma de Brabander

Per Hoffmann

Martien Kas

Bea Campforts

Jesse Swen

Make your next move.